regeneus
living regenerative medicine

ASX Announcement

Regeneus to present at Austrade Mission on Regenerative Medicine Opportunities in Japan

Sydney, Australia – 7 December 2015

Regeneus Ltd (ASX: RGS), a clinical-stage regenerative medicine company, announced today that John Martin, CEO, will present at Austrade's Mission on Regenerative Medicine Opportunities in Japan, on Monday 7 December in Tokyo and Wednesday 9 December in Kobe. A copy of the presentation has been lodged on the ASX Markets Announcement Platform.

Organised by Austrade, the Australian government's export, international education and foreign investment promotion agency, this four-day mission is aimed to promote Australian regenerative medicine technologies and research capabilities and explore collaboration opportunities in Japan. The seminars will be co-hosted by the Forum for Regenerative Medicine (FIRM), the peak industry body in Japan.

The mission will hear from the newly formed Agency for Medical Research and Development (AMED) and the Ministry of Health, Labour and Welfare (MHLW).

Corporate members of FIRM, the Japan Bioindustry Association, companies located in the Kobe Biomedical Precinct, companies of Osaka Pharmaceutical Manufacturers Association as well as government officials and industrial and academic contacts, will attend the mission.

The market in Japan for regenerative medicines is projected to grow to US$12.7bn by 2030 according to the Japanese government. The development of the cell and tissue regeneration industry is one of the pillars of the Growth Strategy of the Abe Administration. In November 2014, Japan introduced new laws to enhance the development of the regenerative market including a significantly shorter approval process for commercialisation of new cell therapies.

Regeneus has targeted the Japanese market for its Progenza allogeneic stem cell therapy for osteoarthritis. The company plans to conduct a phase 2 trial for Progenza in Japan. The company has spent over 12 months in due diligence on the market opportunity and is focused on securing a Japanese manufacturing and clinical partner for Progenza in the near term.

This mission is being held against the backdrop of the commencement in January 2015 of the historic Japan-Australia Economic Partnership Agreement which has been designed to encourage business activity between Australia and its 2nd largest trading partner, Japan.

ENDS

25 Bridge Street, Pymble, NSW 2073
Ph: +61 2 9499 8010 • Fax: +61 2 9499 8020 • www.regeneus.com.au • ABN 13 127 035 358

About Regeneus:

Regeneus Ltd (ASX: RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders and oncology.

The company has two product candidates in Phase 1 trial: Progenza is an allogeneic off-the-shelf adipose stem cell therapy to treat osteoarthritis and other musculoskeletal conditions and RGSH4K is an autologous therapeutic cancer vaccine to treat a wide range of tumour types. The company is developing a stem cell secretions based cream targeting acne and other inflammatory skin conditions. The company has two therapies targeting animal conditions: CryoShot is a clinical-stage allogeneic off-the-shelf adipose stem cell therapy for the treatment of canine and equine osteoarthritis and other musculoskeletal conditions and Kvax is an autologous therapeutic cancer vaccine in clinical trials.

Contact for further information:

Investors:
Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au or go to www.regeneus.com.au